Grant

NIH grant supports Quiver Bioscience’s QV-2421 for pain

Tue, 05 May 2026 09:00:00 -0400

Quiver Bioscience Inc. has received a multi-year grant from the National Institutes of Health (NIH) to advance its lead Nav1.7-targeted antisense oligonucleotide (ASO), QV-2421, through IND-enabling studies and first-in-human trials for chronic neuropathic pain.

CIRM grant to help advance Acurastem’s AS-241 toward clinic

Wed, 29 Apr 2026 09:00:00 -0400

Acurastem Inc. has been awarded $7.5 million in grant funding by the California Institute for Regenerative Medicine (CIRM) to support the advancement of lead clinical candidate AS-241 toward first-in-human testing.

CARB-X award supports Adjane’s gonorrhea vaccine

Tue, 28 Apr 2026 09:00:00 -0400

CARB-X (Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator) is awarding US$2.6 million to Adjane Holding BV to advance the development of a vaccine candidate to prevent infections caused by Neisseria gonorrhoeae.

Sononeu wins $5.2M ARPA-H grant for ultrasound-activated therapeutics

Wed, 08 Apr 2026 09:00:00 -0400

Newco Sononeu Inc. has launched to translate more than a decade of basic research in controlling cells with ultrasound into novel, non-invasive therapies for conditions including peripheral and diabetic neuropathy. The underlying technology of sonogenetics provides the ability to manipulate cellular activity via ultrasound-sensitive ion channels that respond to acoustic pressure. These channels may be endogenous, or could be delivered by targeted vectors to specific cell types.

Sononeu wins $5.2M ARPA-H grant for ultrasound-activated therapeutics

Tue, 07 Apr 2026 11:00:00 -0400

Grant supports Epifrontier’s EPF-001 for β-globin disorders

Wed, 25 Mar 2026 09:00:00 -0400

Epifrontier Therapeutics Inc. has been awarded a grant of up to $32 million in nondilutive funding from the Japan Agency for Medical Research and Development (AMED) to advance the clinical development of EPF-001 (RK-701), a first-in-class G9a inhibitor being developed for sickle cell disease and β-thalassemia.

MJFF grants support Casma’s TRPML1 agonist CSM-101

Wed, 11 Mar 2026 09:00:00 -0400

Casma Therapeutics Inc. has been awarded approximately $7.6 million in funding across two competitive grant programs from The Michael J. Fox Foundation for Parkinson’s Research (MJFF) to support Casma’s lead program, CSM-101.

Acurastem awarded grant to advance SYF2-targeted ALS therapeutics

Wed, 11 Mar 2026 09:00:00 -0400

Acurastem Inc. has received a two-year research grant from Target ALS to advance therapeutics targeting SYF2, a recently identified regulator of TDP-43 function. TDP-43 dysfunction is a central biological hallmark of amyotrophic lateral sclerosis (ALS).

CARB-X supports antibiotic development at Harvard

Thu, 05 Mar 2026 08:00:00 -0500

CARB-X is awarding $1.2 million to the Andrew G. Myers research group at Harvard University to develop enhanced antibiotics that target multidrug-resistant gram-negative bacterial pathogens, including Escherichia coli and Klebsiella pneumoniae, to treat urinary tract infections, pneumonia and bloodstream infections.

Grants support Lario Therapeutics’ calcium channel programs

Fri, 20 Feb 2026 08:00:00 -0500

Lario Therapeutics Ltd. has received a total of $2.4 million in grant funding from The Michael J. Fox Foundation for Parkinson’s Research (MJFF) and Wellcome to support the continued expansion of its neuronal calcium channel drug discovery platform. The funding provides validation of Lario’s work on selective small-molecule inhibitors of voltage-gated neuronal calcium channels.

European grant supports Beactica’s BEA-17 for glioblastoma

Tue, 17 Feb 2026 08:00:00 -0500

Beactica Therapeutics AB, together with researchers at KU Leuven, has been awarded a €2.5 million (US$3.0 million) grant by the European Innovation Council (EIC) to advance BEA-17, a precision immune therapy for glioblastoma.

New push to increase investor interest in UK life sciences research

Wed, 04 Feb 2026 12:00:00 -0500

The U.K.’s main research funding agency is looking to put more public money into proof of concept and pre-seed funding of putative university spinouts, to make them more investible and improve relations between academics and investors. The move by UK Research and Innovation, which in 2026 will allocate £9.22 billion (US$12.58 billion) of taxpayer money across all fields of research, is in response to a government edict that the agency prioritizes outputs over inputs.

Grant supports Ahead Therapeutics’ platform for type 1 diabetes

Fri, 30 Jan 2026 08:00:00 -0500

Ahead Therapeutics SL has been awarded an Industry Discovery and Development Partnership (IDDP) grant from Breakthrough T1D to support progression of the company’s proprietary Mimi-Top (mimicking tolerogenic particles) platform.

MJFF grant supports Bexorg’s translational biomarker work

Thu, 29 Jan 2026 08:00:00 -0500

Bexorg Inc. has been awarded a research grant from The Michael J. Fox Foundation for Parkinson’s Research (MJFF) through the Targets to Therapies initiative to identify translational biomarkers for TRPML1-targeted therapies.

NEI grant supports Fannin’s non-VEGF-targeted program for wet AMD

Mon, 12 Jan 2026 08:00:00 -0500

Fannin Partners LLC has been awarded a $300,000 phase I Small Business Innovation Research (SBIR) grant from the National Eye Institute (NEI) to advance a first-in-class, non-VEGF-targeted therapeutic for wet age-related macular degeneration (AMD) in patients not responding to anti-VEGF therapies.

Alzheimer's Association funds Pramana’s PRM-914

Thu, 08 Jan 2026 08:00:00 -0500

Pramana Pharmaceuticals Inc. has been awarded $1 million from the Alzheimer’s Association to support IND-enabling development of PRM-914, the company’s once-daily oral small-molecule therapeutic for Alzheimer’s disease. The funding will support final toxicology and translational studies required to advance PRM-914 into first-in-human evaluation.

Grant supports Oniria’s ONR-001 for colorectal cancer

Tue, 16 Dec 2025 08:00:00 -0500

Oniria Therapeutics SL, Vall d’Hebron Institute of Oncology (VHIO) and Institut Català d’Investigació Química (ICIQ) have partnered to advance ONR-001 for the treatment of colorectal cancer and to prepare it for clinical trials.

Research grants support early clinical trials of ALS treatments

Fri, 05 Dec 2025 08:00:00 -0500

The ALS Association has announced the recipients of its 2025 Hoffman ALS Clinical Trial Awards. These research grants, worth up to $1 million each, support early-phase trials that generate critical data to accelerate the development of new amyotrophic lateral sclerosis (ALS) treatments.

Grant supports Crossbridge Bio’s CBB-120 toward clinic

Fri, 21 Nov 2025 08:00:00 -0500

Crossbridge Bio Inc. has been awarded a $15 million grant from the Cancer Prevention and Research Institute of Texas (CPRIT) to support completion of IND-enabling activities and advancement of CBB-120 into first-in-human studies.

MJFF grant backs Scineuro’s SNP-614 for Parkinson’s disease

Fri, 21 Nov 2025 08:00:00 -0500

Scineuro Pharmaceuticals Holdings Ltd. has received a $5 million research grant from The Michael J. Fox Foundation for Parkinson’s Research (MJFF) to accelerate the preclinical development of the company’s novel LRRK2-targeted antisense oligonucleotide (ASO) program, SNP-614, for Parkinson’s disease.

Revir reports milestones in HTT-PMS1 Huntington’s disease program

Fri, 21 Nov 2025 08:00:00 -0500

Revir Therapeutics Inc. has announced progress in its HTT-PMS1 genetic medicine program for Huntington’s disease with the identification of a lead compound and the award of a $4.6 million grant from the California Institute for Regenerative Medicine (CIRM).

Grant supports further development of Stemsynergy’s GI cancer drugs

Wed, 29 Oct 2025 09:00:00 -0400

The DeGregorio Family Foundation, with support from the Esophageal Cancer Awareness Association, has awarded an additional $75,000 Michael F. Price Memorial Grant to support research that will provide the groundwork to advance two new drugs – SSTN-302 and SST-1034 – to a phase I clinical trial in patients with advanced upper gastrointestinal cancer.

Grant supports Confo’s work in endocrine and metabolic disorders

Thu, 09 Oct 2025 09:00:00 -0400

Confo Therapeutics NV has secured a 2-year €1 million (US$1.2 million) grant from Flanders Innovation & Entrepreneurship (VLAIO) to advance research and development of ultra-long-acting medicines targeting G protein-coupled receptors (GPCRs), including bi- and multispecific antibody formats for obesity and other metabolic and endocrine disorders.

Award supports Tessera Therapeutics’ in vivo CAR T therapies

Thu, 09 Oct 2025 09:00:00 -0400

Tessera Therapeutics Inc. has been awarded up to $41.3 million from the Advanced Research Projects Agency for Health (ARPA-H) as part of its EMBODY (Engineering of immune cells inside the body) program to support the development of Tessera’s in vivo CAR T therapy efforts.

NIH grant supports Pop Biotechnologies’ Alzheimer’s immunotherapy

Thu, 02 Oct 2025 09:00:00 -0400

Pop Biotechnologies Inc. has been awarded a $2.46 million grant by the National Institutes of Health (NIH) to pursue development of a ‘mosaic’ active immunotherapy against Alzheimer’s disease.

BARDA supports Orexo’s OX-390 for adulterated opioid overdose

Tue, 30 Sep 2025 09:00:00 -0400

Orexo AB’s subsidiary Orexo US Inc. has been awarded $8 million in funding by the U.S. Biomedical Advanced Research and Development Authority (BARDA) to support the development of OX-390, an intranasal rescue medication for adulterated opioid overdoses.

NIDA boost for Atai’s 5-HT2A/2C receptor agonists

Fri, 19 Sep 2025 09:00:00 -0400

Atai Life Sciences NV has been awarded a multiyear, milestone-driven grant worth up to $11.4 million by the National Institute on Drug Abuse (NIDA) to support development of Atai’s novel 5-HT2A/2C receptor agonists with nonhallucinogenic potential for opioid use disorder.

NIAID grant supports pediatric vaccine for HIV

Fri, 19 Sep 2025 09:00:00 -0400

The National Institute of Allergy and Infectious Diseases (NIAID) has awarded a 5-year $20.8 million grant to a multi-institutional team led by Weill Cornell Medicine investigators for advanced preclinical development of a promising experimental HIV vaccine.

Endocyclic’s ENDO-205 awarded NIH grant for endometriosis

Wed, 17 Sep 2025 09:00:00 -0400

Endocyclic Therapeutics (Endomet Biosciences Inc.) has been awarded a National Institute of Health (NIH) Commercialization Readiness Pilot (CRP) Program grant from the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) to accelerate the commercialization of ENDO-205, a nonhormonal, disease-modifying therapeutic designed to treat endometriosis.

Grant supports evaluation of Auravax’s Nanosting-001

Tue, 16 Sep 2025 09:00:00 -0400

Auravax Therapeutics Inc. has received funding from the Gates Foundation to evaluate the efficacy of Nanosting-001 in validated swine models of influenza infection at Kansas State University College of Veterinary Medicine and The Pirbright Institute.